Chairman Charles E. Grassley, right, and ranking member Sen. Ron Wyden are seen before a Senate Finance Committee on drug pricing in America on February 26, 2019. (Tom Williams/CQ Roll Call)
Both the House and the Senate have competing bills aimed at addressing the rising costs of prescription drugs, a legislative priority backed by President Donald Trump.
But what would these various proposals accomplish, and how likely is it they’ll be signed into law?
[jwp-video n=”1″]
Recent Stories
Funding extension passes House, heads for Senate rewrite
Can the GOP trifecta meet their ‘mandate’ moment?
Which direction is Trump’s job approval rating headed?
For Darline Graham, winning Trump’s endorsement may be the easy part
Louisiana’s Cleo Fields forgoes reelection after redistricting eliminated his seat
Republicans in Congress probe history museum, echoing Trump